New pill tested in healthy people: first step toward future treatments

NCT ID NCT05110794

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested an experimental oral drug called LY3502970 in 34 healthy adults. Researchers measured how much of the drug gets into the blood and how the body processes it, both after eating and on an empty stomach. The main goals were to check safety and understand drug levels, not to treat any disease. The study lasted up to 49 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3502970 (an experimental oral drug)
What this could lead to: If successful, this early study will help determine safe dosing for future trials, potentially leading to treatments for conditions like diabetes or obesity.
What could go wrong: This is a very early Phase 1 study in only 34 healthy people. It is designed to check safety and drug levels, not to treat any disease. Many early drugs fail to show benefit in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Lilly Centre for Clinical Pharmacology

Singapore, 138623, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.